{"id":"95dd4b92-bb5c-4d74-834f-d3886cd55fd2","url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal?condition=Disease+area+%E2%80%94+e.g.+%22Obesity%22+%7C+%22Cardiovascular%22+%7C+%22Oncology%22+%7C+%22Rare+Neurological%22+%7C+%22Autoimmune%22&deal_type=acquisition+%7C+licensing+%7C+both+%28default%3A+both%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&stage=phase2+%7C+phase3+%7C+both+%28default%3A+both%29","method":"GET","fingerprint":"78b226b545b58560263713e9ea2bbc774a6d53f0252cdf431c45254e365a1585","name":"ClinicalIntelPulse","description":null,"category":"other","docs_url":null,"advertised_price_usd":"0.350000","asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","scheme":"exact","networks":["eip155:8453","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","eip155:137","eip155:42161","eip155:480","eip155:143","eip155:196","eip155:999","algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","xrpl:0","eip155:56"],"pay_to":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","input_schema":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"stage":{"type":"string"},"condition":{"type":"string"},"deal_type":{"type":"string"}}}},"additionalProperties":false},"output_schema":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}},"schema_completeness":0,"status":"degraded","first_seen_at":"2026-08-23 12:44:14.152782+00","last_seen_at":"2026-08-23 16:50:20.468+00","last_success_at":"2026-09-14 16:35:14.453+00","dead_since":null,"probe_backoff_tier":0,"next_probe_at":"2026-09-14 16:40:14.453+00","search_tsv":"'clinicalintelpuls':1","catalog_number":"7102","x402_version":2,"resource_url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal","resource_description":"Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likely to be acquired or licensed, with acquisition targets, deal comps, transaction multiples and estimated deal values. Worldwide. For biotech-investing and BD agents.","bazaar_extension":{"info":{"input":{"type":"http","method":"GET","queryParams":{"lang":"en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)","stage":"phase2 | phase3 | both (default: both)","condition":"Disease area — e.g. \"Obesity\" | \"Cardiovascular\" | \"Oncology\" | \"Rare Neurological\" | \"Autoimmune\"","deal_type":"acquisition | licensing | both (default: both)"}},"output":{"type":"json","errors":{"400":{"example":{"error":"invalid request"},"description":"Invalid or missing parameter(s). Returned before the payment gate on paid requests, so a malformed call is never charged. JSON body: { error: <what is wrong and how to fix it> } plus usage hints."},"402":{"description":"Payment required — x402 v2 challenge; the accepts array lists scheme, network, and amount. Retry the same request with a PAYMENT-SIGNATURE (v2) or X-PAYMENT (v1) header. Verification is free."},"500":{"example":{"error":"upstream_failed"},"description":"Unexpected server error. If a payment settled without a usable result, contact info@theaslangroupllc.com with the settlement tx hash for a re-run or credit."}},"example":{"query_summary":{"as_of":"2026-06-07","stage":"both","condition":"Obesity","deal_type":"both"},"market_context":{"approved_leaders":["Semaglutide (Novo Nordisk — Wegovy)","Tirzepatide (Lilly — Zepbound)"],"big_pharma_strategic_need":"Roche, AstraZeneca, Pfizer, Amgen all need next-gen obesity assets. Roche acquired Carmot Therapeutics for $2.7B. AZ acquired Eccogene for obesity pipeline.","total_addressable_market_usd_bn":100},"recent_deal_comps":[{"deal":"Roche / Carmot Therapeutics","year":2023,"stage":"PHASE1/2","mechanism":"GLP-1 peptide","value_usd_bn":2.7},{"deal":"AstraZeneca / Eccogene","year":2024,"stage":"PHASE2","mechanism":"Small-molecule GLP-1","value_usd_bn":1.85},{"deal":"Amgen / ChemoCentryx","year":2022,"stage":"Approved","mechanism":"C5aR1","value_usd_bn":3.7}],"acquisition_targets":[{"asset":"Mazdutide (IBI362)","risks":["China geopolitical risk for IP transfer","Phase 3 US/EU data needed before deal close"],"stage":"PHASE3","company":"Innovent Biologics (China)","deal_comp":"Structure Day1 Biosciences (Pfizer) $1.25B + milestones — Phase 2 obesity asset. Mazdutide later-stage = premium.","mechanism":"GLP-1/glucagon dual agonist","probability":"High","clinical_data":"Phase 3 China data strong — 14.5% body weight reduction at 52 weeks","deal_rationale":"Ex-China rights available. Differentiated vs. semaglutide on muscle preservation. Lilly or Roche most likely acquirers.","estimated_deal_value_usd_m":"800-2000"}],"deal_timing_signals":"Obesity M&A is peak hot. Big pharma BD teams are actively searching — any Phase 2 readout with >10% weight loss and clean safety profile will attract inbound interest within 3-6 months of data release.","licensing_opportunities":[{"asset":"CT-388 (dual GLP-1/GIP)","notes":"Roche may sublicense ex-US rights to regional partners in Asia/LatAm","company":"Carmot Therapeutics (acq. Roche)","estimated_license_value_usd_m":"300-800"}]}}},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"stage":{"type":"string"},"condition":{"type":"string"},"deal_type":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}}},"accepted_requirements":[{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":300},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"350000"},{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"GatewayWalletBatched","version":"1","verifyingContract":"0x77777777dcc4d5a8b6e418fd04d8997ef11000ee"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":604900},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"350000"},{"raw":{"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","extra":{"feePayer":"Hc3sdEAsCGQcpgfivywog9uwtk8gUBUZgsxdME1EJy88"},"payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","amount":"350000","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","maxTimeoutSeconds":300},"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","amountAtomic":"350000"},{"raw":{"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:137","maxTimeoutSeconds":300},"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:137","amountAtomic":"350000"},{"raw":{"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:42161","maxTimeoutSeconds":300},"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:42161","amountAtomic":"350000"},{"raw":{"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:480","maxTimeoutSeconds":300},"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:480","amountAtomic":"350000"},{"raw":{"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:143","maxTimeoutSeconds":300},"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:143","amountAtomic":"350000"},{"raw":{"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","extra":{"name":"USD₮0","version":"1"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:196","maxTimeoutSeconds":300},"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:196","amountAtomic":"350000"},{"raw":{"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:999","maxTimeoutSeconds":300},"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:999","amountAtomic":"350000"},{"raw":{"asset":"31566704","extra":{"feePayer":"ZMFK2OI7ZBD2U27ISERZC4S6LKM6WMFJPZQ4MYNJDZ2VNBNMBA67RA22AA"},"payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","amount":"350000","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","maxTimeoutSeconds":300},"asset":"31566704","payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","amountAtomic":"350000"},{"raw":{"asset":"XRP","extra":{"invoiceId":"E3B9328A239640DB96F93516AF1F8FEC","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"350000","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"XRP","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"350000"},{"raw":{"asset":"524C555344000000000000000000000000000000","extra":{"issuer":"rMxCKbEDwqr76QuheSUMdEGf4B9xJ8m5De","invoiceId":"8CC7551EB1C04ED0BADBD48E53205CBE","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"0.35","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"524C555344000000000000000000000000000000","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"0.35"},{"raw":{"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","extra":{"name":"World Liberty Financial USD","version":"1","signerAddress":"0x34F7a661160780Ce1346e6D7B96D2bE244590899","assetTransferMethod":"eip3009"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000000000000000","scheme":"exact","network":"eip155:56","maxTimeoutSeconds":300},"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:56","amountAtomic":"350000000000000000"}],"bazaar_compatible":true,"bazaar_validated_at":"2026-09-14 16:35:14.453+00","bazaar_validation_error":null,"window":"24h","probes_n":22,"handshake_uptime":0.90909094,"settle_success_rate":0,"valid_result_rate":null,"latency_p50":657,"latency_p90":4272,"price_drift_pct":0,"score":0.6498,"computed_at":"2026-09-14 16:35:22.935+00","source_metadata":[{"raw":{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal?condition=Disease+area+%E2%80%94+e.g.+%22Obesity%22+%7C+%22Cardiovascular%22+%7C+%22Oncology%22+%7C+%22Rare+Neurological%22+%7C+%22Autoimmune%22&deal_type=acquisition+%7C+licensing+%7C+both+%28default%3A+both%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&stage=phase2+%7C+phase3+%7C+both+%28default%3A+both%29","name":"ClinicalIntelPulse","method":"GET","source":"bazaar:api.cdp.coinbase.com","fingerprint":"78b226b545b58560263713e9ea2bbc774a6d53f0252cdf431c45254e365a1585","advertisedPriceUsd":0.35},"source_id":1,"external_id":null}],"live_endpoint_metadata":{"x402_version":2,"resource_url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal","resource_description":"Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likely to be acquired or licensed, with acquisition targets, deal comps, transaction multiples and estimated deal values. Worldwide. For biotech-investing and BD agents.","bazaar_extension":{"info":{"input":{"type":"http","method":"GET","queryParams":{"lang":"en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)","stage":"phase2 | phase3 | both (default: both)","condition":"Disease area — e.g. \"Obesity\" | \"Cardiovascular\" | \"Oncology\" | \"Rare Neurological\" | \"Autoimmune\"","deal_type":"acquisition | licensing | both (default: both)"}},"output":{"type":"json","errors":{"400":{"example":{"error":"invalid request"},"description":"Invalid or missing parameter(s). Returned before the payment gate on paid requests, so a malformed call is never charged. JSON body: { error: <what is wrong and how to fix it> } plus usage hints."},"402":{"description":"Payment required — x402 v2 challenge; the accepts array lists scheme, network, and amount. Retry the same request with a PAYMENT-SIGNATURE (v2) or X-PAYMENT (v1) header. Verification is free."},"500":{"example":{"error":"upstream_failed"},"description":"Unexpected server error. If a payment settled without a usable result, contact info@theaslangroupllc.com with the settlement tx hash for a re-run or credit."}},"example":{"query_summary":{"as_of":"2026-06-07","stage":"both","condition":"Obesity","deal_type":"both"},"market_context":{"approved_leaders":["Semaglutide (Novo Nordisk — Wegovy)","Tirzepatide (Lilly — Zepbound)"],"big_pharma_strategic_need":"Roche, AstraZeneca, Pfizer, Amgen all need next-gen obesity assets. Roche acquired Carmot Therapeutics for $2.7B. AZ acquired Eccogene for obesity pipeline.","total_addressable_market_usd_bn":100},"recent_deal_comps":[{"deal":"Roche / Carmot Therapeutics","year":2023,"stage":"PHASE1/2","mechanism":"GLP-1 peptide","value_usd_bn":2.7},{"deal":"AstraZeneca / Eccogene","year":2024,"stage":"PHASE2","mechanism":"Small-molecule GLP-1","value_usd_bn":1.85},{"deal":"Amgen / ChemoCentryx","year":2022,"stage":"Approved","mechanism":"C5aR1","value_usd_bn":3.7}],"acquisition_targets":[{"asset":"Mazdutide (IBI362)","risks":["China geopolitical risk for IP transfer","Phase 3 US/EU data needed before deal close"],"stage":"PHASE3","company":"Innovent Biologics (China)","deal_comp":"Structure Day1 Biosciences (Pfizer) $1.25B + milestones — Phase 2 obesity asset. Mazdutide later-stage = premium.","mechanism":"GLP-1/glucagon dual agonist","probability":"High","clinical_data":"Phase 3 China data strong — 14.5% body weight reduction at 52 weeks","deal_rationale":"Ex-China rights available. Differentiated vs. semaglutide on muscle preservation. Lilly or Roche most likely acquirers.","estimated_deal_value_usd_m":"800-2000"}],"deal_timing_signals":"Obesity M&A is peak hot. Big pharma BD teams are actively searching — any Phase 2 readout with >10% weight loss and clean safety profile will attract inbound interest within 3-6 months of data release.","licensing_opportunities":[{"asset":"CT-388 (dual GLP-1/GIP)","notes":"Roche may sublicense ex-US rights to regional partners in Asia/LatAm","company":"Carmot Therapeutics (acq. Roche)","estimated_license_value_usd_m":"300-800"}]}}},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"stage":{"type":"string"},"condition":{"type":"string"},"deal_type":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}}},"accepted_requirements":[{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":300},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"350000"},{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"GatewayWalletBatched","version":"1","verifyingContract":"0x77777777dcc4d5a8b6e418fd04d8997ef11000ee"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":604900},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"350000"},{"raw":{"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","extra":{"feePayer":"Hc3sdEAsCGQcpgfivywog9uwtk8gUBUZgsxdME1EJy88"},"payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","amount":"350000","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","maxTimeoutSeconds":300},"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","amountAtomic":"350000"},{"raw":{"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:137","maxTimeoutSeconds":300},"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:137","amountAtomic":"350000"},{"raw":{"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:42161","maxTimeoutSeconds":300},"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:42161","amountAtomic":"350000"},{"raw":{"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:480","maxTimeoutSeconds":300},"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:480","amountAtomic":"350000"},{"raw":{"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:143","maxTimeoutSeconds":300},"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:143","amountAtomic":"350000"},{"raw":{"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","extra":{"name":"USD₮0","version":"1"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:196","maxTimeoutSeconds":300},"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:196","amountAtomic":"350000"},{"raw":{"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000","scheme":"exact","network":"eip155:999","maxTimeoutSeconds":300},"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:999","amountAtomic":"350000"},{"raw":{"asset":"31566704","extra":{"feePayer":"ZMFK2OI7ZBD2U27ISERZC4S6LKM6WMFJPZQ4MYNJDZ2VNBNMBA67RA22AA"},"payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","amount":"350000","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","maxTimeoutSeconds":300},"asset":"31566704","payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","amountAtomic":"350000"},{"raw":{"asset":"XRP","extra":{"invoiceId":"E3B9328A239640DB96F93516AF1F8FEC","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"350000","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"XRP","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"350000"},{"raw":{"asset":"524C555344000000000000000000000000000000","extra":{"issuer":"rMxCKbEDwqr76QuheSUMdEGf4B9xJ8m5De","invoiceId":"8CC7551EB1C04ED0BADBD48E53205CBE","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"0.35","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"524C555344000000000000000000000000000000","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"0.35"},{"raw":{"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","extra":{"name":"World Liberty Financial USD","version":"1","signerAddress":"0x34F7a661160780Ce1346e6D7B96D2bE244590899","assetTransferMethod":"eip3009"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"350000000000000000","scheme":"exact","network":"eip155:56","maxTimeoutSeconds":300},"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:56","amountAtomic":"350000000000000000"}],"bazaar_compatible":true,"bazaar_validated_at":"2026-09-14 16:35:14.453+00","bazaar_validation_error":null},"sonar_metrics":{"score":0.6498,"uptime":0.90909094,"paid_success_rate":0,"valid_result_rate":null,"latency_p50":657,"latency_p90":4272,"price_drift_pct":0},"cdp_indexed":false,"confidence":"high"}